Following the creation of InSynchrony Ventures in 2016 and the announcement of our new strategic investment vehicle in April 2017 (http://www.insymbiosis.com/blog-posts/introducing-insymbiosis-strategic-investment-vehicle/) we are now excited to launch the InSynchrony Ventures website.
InSynchrony Ventures is a strategic investment vehicle that specializes in funding earlier staged biopharma companies with assets that are between preclinical and early clinical phases of development. We strongly believe in combining investment capital, drug development expertise and the right timing in order to provide early staged assets with the best chances of success. Therefore, we strongly collaborate with InSymbiosis, a collaborative drug development company previously founded by Dr Dean Wenham (and founder of InSynchrony Ventures) in order to inject expert drug development skills and a very unique outsourcing model alongside the capital provided by InSynchrony Ventures.
So far, we have invested in 5 companies located in both the US and Europe and covering the areas of oncology, infectious disease, mens health and fibrosis. We are further evaluating many additional investment opportunities and our target is to invest in 3 and 5 companies each year.
Previous investment news related to InSynchrony Ventures can be found on the InSymbiosis website (http://www.insymbiosis.com/blog/) but going forward, InSynchrony Ventures will host is own blog and news flow from our new website.
To find out more about InSynchrony Ventures we welcome you to reach out via info@Insynchronyventures.com or submit a project via our website.
Dean Wenham, PhD
Partner and CEO of InSynchrony Ventures Inc
Copyright © 2017 InSynchrony Ventures. All rights reserved. Creation by Netfolie.com